Skip to main content
Top
Published in: Clinical & Experimental Metastasis 6/2007

01-10-2007 | Research Paper

The protein kinase C inhibitor, H7, inhibits tumor cell invasion and metastasis in mouse melanoma via suppression of ERK1/2

Authors: Masanobu Tsubaki, Hiroshi Matsuoka, Chikako Yamamoto, Chisato Kato, Mitsuhiko Ogaki, Takao Satou, Tatsuki Itoh, Takashi Kusunoki, Yoshihiro Tanimori, Shozo Nishida

Published in: Clinical & Experimental Metastasis | Issue 6/2007

Login to get access

Abstract

Protein kinase C (PKC) has been shown to be a signal transducer during tumorigenesis, tumor cell invasion, and metastasis. Recent studies have reported that the PKC inhibitor, 7-hydroxystaurosporine, inhibits tumor cell invasion. However, the molecular mechanisms of this inhibition of invasion and metastasis are not well understood. In the present study, we attempt to clarify the mechanism by which H7, a PKC inhibitor, inhibits tumor cell invasion and metastasis in the melanoma cell line B16BL6. It was found that H7 inhibits B16BL6 cell invasion and metastasis. We also observed that H7 inhibits the mRNA expression and protein activities of matrix metalloproteinase (MMP)-1, -2, -9 and MT1-MMP. Furthermore, H7 suppresses phosphorylated extracellular signal-regulated kinase 1/2 (ERK1/2). However, other signal transduction factors, such as p38 mitogen-activated protein kinase (p38MAPK) and c-Jun N-terminal kinase 1/2 (JNK1/2), were unaffected. Moreover, U0126, a MEK1/2 inhibitor, also inhibited B16BL6 cell invasion and metastasis, as well as the mRNA expression and protein activities of MMP-1, -2, -9 and MT1-MMP. This indicates that H7 inhibits signal transduction through the PKC/MEK/ERK pathway, thereby inhibiting B16BL6 cell invasion and metastasis. These results suggest that PKC inhibitors have potential clinical applications in the treatment of tumor cell metastasis.
Literature
3.
go back to reference Liotta LA, Tryggvason K, Garbisa S, et al (1980) Metastatic potential correlates with enzymatic degradation of basement membranes collagen. Nature 284:67–68PubMedCrossRef Liotta LA, Tryggvason K, Garbisa S, et al (1980) Metastatic potential correlates with enzymatic degradation of basement membranes collagen. Nature 284:67–68PubMedCrossRef
4.
go back to reference Nikkola J, Vihinen P, Vuoristo MS, et al (2005) High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma. Clin Cancer Res 11:5158–5166PubMedCrossRef Nikkola J, Vihinen P, Vuoristo MS, et al (2005) High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma. Clin Cancer Res 11:5158–5166PubMedCrossRef
5.
go back to reference Hofmann UB, Westphal JR, Van Muijen GN, Ruiter DJ (2000) Matrix metalloproteinases in human melanoma. J Invest Dermatol 115:337–344PubMedCrossRef Hofmann UB, Westphal JR, Van Muijen GN, Ruiter DJ (2000) Matrix metalloproteinases in human melanoma. J Invest Dermatol 115:337–344PubMedCrossRef
7.
go back to reference Hidalgo M, Eckhardt SG (2001) Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst 93:178–193PubMedCrossRef Hidalgo M, Eckhardt SG (2001) Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst 93:178–193PubMedCrossRef
8.
go back to reference Eccles SA (2004) Parallels in invasion and angiogenesis provide pivotal points for therapeutic intervention. Int J Dev Biol 48:583–598PubMedCrossRef Eccles SA (2004) Parallels in invasion and angiogenesis provide pivotal points for therapeutic intervention. Int J Dev Biol 48:583–598PubMedCrossRef
9.
go back to reference Zucker S, Cao J, Chen WT (2000) Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene 19:6642–6650PubMedCrossRef Zucker S, Cao J, Chen WT (2000) Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene 19:6642–6650PubMedCrossRef
10.
go back to reference Lahn M, Sundell K, Koheler G (2006) The role of protein kinase C-alpha in hematologic malignancies. Acta Hematol 115:1–8CrossRef Lahn M, Sundell K, Koheler G (2006) The role of protein kinase C-alpha in hematologic malignancies. Acta Hematol 115:1–8CrossRef
11.
go back to reference Lahn MM, Sundell KL (2004) The role of protein kinase C-alpha (PKC-alpha) in melanoma. Melanoma Res 2:85–89CrossRef Lahn MM, Sundell KL (2004) The role of protein kinase C-alpha (PKC-alpha) in melanoma. Melanoma Res 2:85–89CrossRef
12.
go back to reference Raso E, Tovari J, Toth K, et al (2001) Ectopic alphaIIbbeta3 integrin signaling involves 12-lipoxygenase- and PKC-mediated serine phosphorylation events in melanoma cells. Thromb Haemost 85:1037–1042PubMed Raso E, Tovari J, Toth K, et al (2001) Ectopic alphaIIbbeta3 integrin signaling involves 12-lipoxygenase- and PKC-mediated serine phosphorylation events in melanoma cells. Thromb Haemost 85:1037–1042PubMed
13.
14.
go back to reference Batlle E, Verdu J, Dominguez D, et al (1998) Protein kinase C-alpha activity inversely modulates invasion and growth of intestinal cells. J Biol Chem 273:15091–15098PubMedCrossRef Batlle E, Verdu J, Dominguez D, et al (1998) Protein kinase C-alpha activity inversely modulates invasion and growth of intestinal cells. J Biol Chem 273:15091–15098PubMedCrossRef
15.
go back to reference Berrier AL, Mastrangelo AM, Downward J, et al (2000) Activated R-ras, Rac1, PI 3-kinase and PKCepsilon can each restore cell spreading inhibited by isolated integrin beta1 cytoplasmic domains. J Cell Biol 151:1549–1560PubMedCrossRef Berrier AL, Mastrangelo AM, Downward J, et al (2000) Activated R-ras, Rac1, PI 3-kinase and PKCepsilon can each restore cell spreading inhibited by isolated integrin beta1 cytoplasmic domains. J Cell Biol 151:1549–1560PubMedCrossRef
16.
go back to reference Chun JS, Ha MJ, Jacobson BS (1996) Differential translocation of protein kinase C epsilon during HeLa cell adhesion to a gelatin substratum. J Biol Chem 271:13008–13012PubMedCrossRef Chun JS, Ha MJ, Jacobson BS (1996) Differential translocation of protein kinase C epsilon during HeLa cell adhesion to a gelatin substratum. J Biol Chem 271:13008–13012PubMedCrossRef
17.
go back to reference Regala RP, Weems C, Jamieson L, et al (2005) Atypical protein kinase C iota is an oncogene in human non-small cell lung cancer. Cancer Res 65:8905–8911PubMedCrossRef Regala RP, Weems C, Jamieson L, et al (2005) Atypical protein kinase C iota is an oncogene in human non-small cell lung cancer. Cancer Res 65:8905–8911PubMedCrossRef
18.
go back to reference Laudanna C, Sorio C, Tecchio C, et al (2003) Motility analysis of pancreatic adenocarcinoma cells reveals a role for the atypical zeta isoform of protein kinase C in cancer cell movement. Lab Invest 83:1155–1163PubMedCrossRef Laudanna C, Sorio C, Tecchio C, et al (2003) Motility analysis of pancreatic adenocarcinoma cells reveals a role for the atypical zeta isoform of protein kinase C in cancer cell movement. Lab Invest 83:1155–1163PubMedCrossRef
19.
go back to reference Meng QH, Zhou LX, Luo JL, et al (2005) Effect of 7-hydroxystaurosporine on glioblastoma cell invasion and migration. Acta Pharmacol Sin 26:492–499PubMedCrossRef Meng QH, Zhou LX, Luo JL, et al (2005) Effect of 7-hydroxystaurosporine on glioblastoma cell invasion and migration. Acta Pharmacol Sin 26:492–499PubMedCrossRef
20.
go back to reference Vincenti MP, White LA, Schroen DJ, et al (1996) Regulating expression of the gene for matrix metalloproteinase-1 (collagenase): mechanisms that control enzyme activity, transcription, and mRNA stability. Crit Rev Eukaryot Gene Expr 6:391–411PubMed Vincenti MP, White LA, Schroen DJ, et al (1996) Regulating expression of the gene for matrix metalloproteinase-1 (collagenase): mechanisms that control enzyme activity, transcription, and mRNA stability. Crit Rev Eukaryot Gene Expr 6:391–411PubMed
21.
go back to reference Bianchini F, D’Alessio S, Fibbi G, et al (2006) Cytokine-dependent invasiveness in B16 murine melanoma cells: role of uPA system and MMP-9. Oncol Rep 15:709–714PubMed Bianchini F, D’Alessio S, Fibbi G, et al (2006) Cytokine-dependent invasiveness in B16 murine melanoma cells: role of uPA system and MMP-9. Oncol Rep 15:709–714PubMed
22.
go back to reference Yeh MW, Rougier JP, Park JW, et al (2006) Differentiated thyroid cancer cell invasion is regulated through epidermal growth factor receptor-dependent activation of matrix metalloproteinase (MMP)-2/gelatinase A. Endocr Relat Cancer 13:1173–1183PubMedCrossRef Yeh MW, Rougier JP, Park JW, et al (2006) Differentiated thyroid cancer cell invasion is regulated through epidermal growth factor receptor-dependent activation of matrix metalloproteinase (MMP)-2/gelatinase A. Endocr Relat Cancer 13:1173–1183PubMedCrossRef
23.
go back to reference Van Meter TE, Broaddus WC, Rooprai HK, et al (2004) Induction of membrane-type-1 matrix metalloproteinase by epidermal growth factor-mediated signaling in gliomas. Neuro-oncol 6:188–199PubMedCrossRef Van Meter TE, Broaddus WC, Rooprai HK, et al (2004) Induction of membrane-type-1 matrix metalloproteinase by epidermal growth factor-mediated signaling in gliomas. Neuro-oncol 6:188–199PubMedCrossRef
24.
go back to reference Kerkela E, Saarialho-Kere U (2003) Matrix metalloproteinases in tumor progression: focus on basal and squamous cell skin cancer. Exp Dermatol 12:109–125PubMedCrossRef Kerkela E, Saarialho-Kere U (2003) Matrix metalloproteinases in tumor progression: focus on basal and squamous cell skin cancer. Exp Dermatol 12:109–125PubMedCrossRef
25.
go back to reference Ko CH, Shen SC, Lee TJ, et al (2005) Myricetin inhibits matrix metalloproteinase 2 protein expression and enzyme activity in colorectal carcinoma cells. Mol Cancer Ther 4:281–290PubMed Ko CH, Shen SC, Lee TJ, et al (2005) Myricetin inhibits matrix metalloproteinase 2 protein expression and enzyme activity in colorectal carcinoma cells. Mol Cancer Ther 4:281–290PubMed
26.
go back to reference Takino T, Watanabe Y, Matsui M, et al (2006) Membrane-type 1 matrix metalloproteinase modulates focal adhesion stability and cell migration. Exp Cell Res 312:1381–1389PubMedCrossRef Takino T, Watanabe Y, Matsui M, et al (2006) Membrane-type 1 matrix metalloproteinase modulates focal adhesion stability and cell migration. Exp Cell Res 312:1381–1389PubMedCrossRef
27.
go back to reference Huntington JT, Shields JM, Der CJ, et al (2004) Overexpression of collagenase 1 (MMP-1) is mediated by the ERK pathway in invasive melanoma cells: role of BRAF mutation and fibroblast growth factor signaling. J Biol Chem 279:33168–33176PubMedCrossRef Huntington JT, Shields JM, Der CJ, et al (2004) Overexpression of collagenase 1 (MMP-1) is mediated by the ERK pathway in invasive melanoma cells: role of BRAF mutation and fibroblast growth factor signaling. J Biol Chem 279:33168–33176PubMedCrossRef
28.
go back to reference Hah N, Lee ST (2003) An absolute role of the PKC-dependent NF-kappaB activation for induction of MMP-9 in hepatocellular carcinoma cells. Biochem Biophys Res Commun 305:428–433PubMedCrossRef Hah N, Lee ST (2003) An absolute role of the PKC-dependent NF-kappaB activation for induction of MMP-9 in hepatocellular carcinoma cells. Biochem Biophys Res Commun 305:428–433PubMedCrossRef
Metadata
Title
The protein kinase C inhibitor, H7, inhibits tumor cell invasion and metastasis in mouse melanoma via suppression of ERK1/2
Authors
Masanobu Tsubaki
Hiroshi Matsuoka
Chikako Yamamoto
Chisato Kato
Mitsuhiko Ogaki
Takao Satou
Tatsuki Itoh
Takashi Kusunoki
Yoshihiro Tanimori
Shozo Nishida
Publication date
01-10-2007
Publisher
Springer Netherlands
Published in
Clinical & Experimental Metastasis / Issue 6/2007
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-007-9080-z

Other articles of this Issue 6/2007

Clinical & Experimental Metastasis 6/2007 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine